Having access to this important option can make an appreciable difference,’ explained Dr. Derek Jonker, oncologist at the Ottawa Cancer tumor Centre. ‘Access to the latest proven advancements allows us to make treatment options that ensure the best possible patient care to your sufferers.’ The randomized multi-centre Stage II trial referred to as the ‘BOND’ research provided the clinical proof supporting the usage of ERBITUX in conjunction with irinotecan or with chemotherapy. In this scholarly study, the combination therapy demonstrated a substantial response rate of 22.9 percent, a time to progression of 4.1 months, and resulted in 55.5 percent of patients to either get a response or stabilize their disease.Rather, it is Houston's offensive to attain more than 1 million people across 600 square miles who don't have medical health insurance and connect them with the new federal medical health insurance plan that began accepting applications this month. The press is happening in another of the nation's reddest states, a good example of the gap between your vitriolic political opposition to President Barack Obama's signature initiative in some conservative bastions and the actual response to it by community officials . This content was reprinted from kaiserhealthnews.org with permission from the Henry J.